Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inge-Marie Obdeijn

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 9, 2017
Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysisXuan-Anh Phi, Nehmat Houssami, Maartje J Hooning, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2014
Magnetic resonance imaging improves breast screening sensitivity in BRCA mutation carriers age ≥ 50 years: evidence from an individual patient data meta-analysisXuan-Anh Phi, Nehmat Houssami, Inge-Marie Obdeijn, et al.
BMC Cancer|October 4, 2012
Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trialSepideh Saadatmand, Emiel J T Rutgers, Rob A E M Tollenaar, et al.
The New England Journal of Medicine|July 30, 2004
Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predispositionMieke Kriege, Cecile T M Brekelmans, Carla Boetes, et al.
Breast Cancer Research and Treatment|May 4, 2022
Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort studyMark van Barele, Amy Rieborn, Bernadette A M Heemskerk-Gerritsen, et al.
Breast Cancer Research and Treatment|July 15, 2019
Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriersBernadette A M Heemskerk-Gerritsen, Agnes Jager, Linetta B Koppert, et al.
Breast Cancer Research and Treatment|June 23, 2006
Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancerMieke Kriege, Cecile T M Brekelmans, Inge Marie Obdeijn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2010
BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening StudyAdriana J Rijnsburger, Inge-Marie Obdeijn, Reinoutje Kaas, et al.
The Lancet. Oncology|June 22, 2019
MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trialSepideh Saadatmand, H Amarens Geuzinge, Emiel J T Rutgers, et al.
JAMA Oncology|July 31, 2020
Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial RiskH Amarens Geuzinge, Inge-Marie Obdeijn, Emiel J T Rutgers, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
European Journal of Cancer (Oxford, England : 1990)|September 9, 2017
Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysisXuan-Anh Phi, Nehmat Houssami, Maartje J Hooning, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2014
Magnetic resonance imaging improves breast screening sensitivity in BRCA mutation carriers age ≥ 50 years: evidence from an individual patient data meta-analysisXuan-Anh Phi, Nehmat Houssami, Inge-Marie Obdeijn, et al.
BMC Cancer|October 4, 2012
Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trialSepideh Saadatmand, Emiel J T Rutgers, Rob A E M Tollenaar, et al.
The New England Journal of Medicine|July 30, 2004
Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predispositionMieke Kriege, Cecile T M Brekelmans, Carla Boetes, et al.
Breast Cancer Research and Treatment|May 4, 2022
Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort studyMark van Barele, Amy Rieborn, Bernadette A M Heemskerk-Gerritsen, et al.
Breast Cancer Research and Treatment|July 15, 2019
Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriersBernadette A M Heemskerk-Gerritsen, Agnes Jager, Linetta B Koppert, et al.
Breast Cancer Research and Treatment|June 23, 2006
Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancerMieke Kriege, Cecile T M Brekelmans, Inge Marie Obdeijn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2010
BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening StudyAdriana J Rijnsburger, Inge-Marie Obdeijn, Reinoutje Kaas, et al.
The Lancet. Oncology|June 22, 2019
MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trialSepideh Saadatmand, H Amarens Geuzinge, Emiel J T Rutgers, et al.
JAMA Oncology|July 31, 2020
Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial RiskH Amarens Geuzinge, Inge-Marie Obdeijn, Emiel J T Rutgers, et al.
Pageof 4